Gdansk

• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P … Pending
  2025-525009-18-00 5 Pancreatic Ductal Adenocarcinoma
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 5 Hodgkin lymphoma
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting
  2025-522434-32-00 5 2026-07-01 Hemophilia A Without Inhibitors
• A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8 … Recruiting
  2025-524575-22-00 10 2026-06-30 Neovascular age-related macular degeneration (NVAMD)
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Recruiting
  2025-521390-14-00 4 2026-06-22 Acute Myeloid Leukemia
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting
  2025-522435-33-00 5 2026-06-17 Hemophilia A
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE … Recruiting
  2025-522775-29-00 5 2026-06-05 Depressive episodes associated with Bipolar disorder I or II (Bipolar
• An Open-label Study of Azetukalner in Major Depressive Disorder Recruiting
  2025-523618-10-00 5 2026-06-04 Major Depressive Disorder
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis
• Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the ass … Recruiting
  2024-518835-13-00 5 2026-05-19 Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting
  2025-522257-19-00 10 2026-05-12 Relapsing Multiple Sclerosis
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-12 Uncontrolled Moderate to Severe Eosinophilic Asthma
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting
  2024-512248-47-00 9 2026-04-15 Non-small Cell Lung Cancer (NSCLC)
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)

Showing 49–72 of 862 trials